CLAIMS

1. Use of a composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID) for the manufacture of a medicament for reducing bladder spasms in a subject.

2. The use of Claim 1, wherein the NSAID is selected from the group consisting of aspirin, ibuprofen, naproxen sodium, naproxen, indomethacin, nabumetone, salts thereof and combination thereof.

3. The use of Claim 1 or 2, wherein the NSAID is ibuprofen.

4. The use of any one of Claims 1-3, wherein said medicament is formulated for immediate-release, delayed-release, or extended-release.

5. The use of any one of Claims 1-4, wherein said medicament is formulated for oral administration.

6. The use of Claim 5, wherein said medicament is formulated in an orally disintegrating formulation.

7. The use of any one of Claims 1-5, wherein said medicament is coated with an enteric coating.

8. The use of any one of Claims 1-7, wherein said composition further comprises a PG pathway inhibitor, an analgesic, an antimuscarinic agent, an antidiuretic, a spasmolytic, zolpidem or combination thereof.

9. The use of Claim 8, wherein the PG pathway inhibitor is an inhibitor of prostaglandin activity, an inhibitor of prostaglandin transporter activity, an inhibitor of prostaglandin transporter expression, an inhibitor of prostaglandin receptor activity or an inhibitor of prostaglandin receptor expression.

10. Use of a composition comprising an effective amount of a prostaglandin (PG) pathway inhibitor, for the manufacture of a medicament for reducing bladder spasms in a subject, wherein the PG pathway inhibitor is not acetaminophen or an NSAID.

11. The use of Claim 10, wherein the PG pathway inhibitor is an inhibitor of prostaglandin activity, an inhibitor of prostaglandin transporter activity, an inhibitor of prostaglandin transporter expression, an inhibitor of prostaglandin receptor activity or an inhibitor of prostaglandin receptor expression.

12. The use of Claim 10 or 11, wherein the medicament is formulated for immediate-release, delayed-release or extended-release.

13. A pharmaceutical composition for treating bladder spasms, comprising:

one or more PG pathway inhibitors; and

a pharmaceutically acceptable carrier,

wherein the one or more PG pathway inhibitors do not include acetaminophen or an NSAID.

14. The pharmaceutical composition of Claim 13, wherein the PG pathway inhibitor is an inhibitor of prostaglandin activity, an inhibitor of prostaglandin transporter activity, an inhibitor of prostaglandin transporter expression, an inhibitor of prostaglandin receptor activity or an inhibitor of prostaglandin receptor expression.

15. The pharmaceutical composition of Claim 13 or 14, wherein the medicament is formulated for immediate-release, delayed-release or extended-release.